Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3186363 | Annales de Dermatologie et de Vénéréologie | 2014 | 10 Pages |
Abstract
While toxicity of targeted anticancer therapies on the oral mucosa seems relatively frequent in clinical practice, it has not been properly characterized to date, apart from aphthous-like lesions due to mTOR inhibitors. Herein, we report the main oral lesions associated with these new therapies, with a description of the most frequent but also the most characteristic clinical manifestations of these drugs, such as anti-EGFR-induced mucositis, BRAF-inhibitor-associated hyperkeratosis, benign migratory glossitis and osteonecrosis of the jaw observed with angiogenesis inhibitors, as well as lesions more specifically linked with imatinib.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
V. Sibaud, F. Boralevi, E. Vigarios, J.-C. Fricain,